Cullen Frost Bankers Inc. Has $1.07 Million Stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Cullen Frost Bankers Inc. boosted its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 55.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 13,714 shares of the company’s stock after purchasing an additional 4,908 shares during the period. Cullen Frost Bankers Inc.’s holdings in GE HealthCare Technologies were worth $1,072,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. D1 Capital Partners L.P. bought a new position in shares of GE HealthCare Technologies in the third quarter worth about $268,159,000. Van ECK Associates Corp lifted its holdings in shares of GE HealthCare Technologies by 107.3% in the fourth quarter. Van ECK Associates Corp now owns 4,841,652 shares of the company’s stock worth $378,520,000 after acquiring an additional 2,506,417 shares during the last quarter. State Street Corp lifted its holdings in shares of GE HealthCare Technologies by 7.8% in the third quarter. State Street Corp now owns 18,615,890 shares of the company’s stock worth $1,747,101,000 after acquiring an additional 1,347,114 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in shares of GE HealthCare Technologies in the third quarter worth about $93,713,000. Finally, Jennison Associates LLC lifted its holdings in shares of GE HealthCare Technologies by 124.5% in the fourth quarter. Jennison Associates LLC now owns 1,709,635 shares of the company’s stock worth $133,659,000 after acquiring an additional 948,017 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GEHC has been the subject of a number of research reports. Citigroup increased their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their target price for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. Finally, Wells Fargo & Company raised their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $97.67.

GE HealthCare Technologies Stock Up 1.4 %

Shares of NASDAQ GEHC opened at $86.58 on Friday. The company has a market capitalization of $39.59 billion, a P/E ratio of 20.00, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. The company’s 50 day moving average price is $86.63 and its 200-day moving average price is $86.13.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. The firm had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. Equities analysts forecast that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.